Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Valero Energy Corporation (VLO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Valero Energy Corporation — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Valero Energy Corporation trades at $284.51 (market cap $83.35B). The key difference: Valero Energy Corporation is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Valero Energy Corporation pays a 1.71% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | VLO | |
|---|---|---|
Market Cap | $39.89B | $83.35B |
Sector | Health | Energy |
52-Week High | $491.22 | $282.88 |
52-Week Low | $278.09 | $131.77 |
Enterprise Value | $38.15B | $89.10B |
Dividend Yield | — | 1.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Valero Energy (VLO) trades at $280.69, down 0.2% on the day, with strong technical momentum as the stock approaches resistance near $285. The company has consistently beaten earnings estimates for three consecutive quarters, with Q2 2026 expected at $10.03 EPS. Fundamentals show solid profitability with 17.72% ROE and improving cash flow projections for 2026. Recent news highlights strong refining margins and Gulf Coast operational advantages supporting the bullish outlook.
VLO presents a compelling investment case with strong earnings momentum and favorable industry dynamics, though investors face risks from energy market volatility and declining revenue trends. The stock trades above the consensus price target of $257.57, suggesting limited near-term upside despite 58% analyst buy ratings. The upcoming dividend payment of $1.20 provides additional shareholder return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
